Terminated/Withdrawn
Sponsor ID
20160445
Study Evaluating AMG 424 in Subjects with Multiple Myeloma
Study Details
A multi-center Phase 1, First-in-Human study conducted in 2 Parts, testing AMG 424 in subjects with relapsed/ refractory multiple myeloma.
Protocol Summary
Primary Outcome Measures
Subject incidence of treatment emergent and treatment related adverse events as assessed by CTCAE version 4.0
Timeframe: 12 Months
Subject incidence of dose limiting toxicities (DLTs)
Timeframe: 28 Days
Secondary Outcome Measures
Anti-tumor activity
Timeframe: 48 Months
Duration of Response
Timeframe: 48 Months
Maximum concentration (Cmax) of AMG 424
Timeframe: 12 Weeks
Minimum concentration (Cmin) of AMG 424
Timeframe: 12 Weeks
Time of maximum concentration (Tmax) of AMG 424
Timeframe: 12 Weeks
Area under the concentration-time curve (AUC) of AMG 424
Timeframe: 12 Weeks
Time to progression
Timeframe: 48 Months
Progression-Free Survival
Timeframe: 48 Months
Overall Survival
Timeframe: 48 Months
Locations
Location
Research Site
Fitzroy, VIC, VIC, Australia, 3065
Status
Recruiting
Location
Research Site
Winston-Salem, NC, United States, 27157
Status
Recruiting
Location
Research Site
Camperdown, NSW, Australia, 2050
Status
Recruiting
Location
Research Site
Charlotte, NC, United States, 28204
Status
Recruiting
Location
Research Site
Milwaukee, WI, United States, 53226
Status
Recruiting
Location
Research Site
Seattle, WA, United States, 98104
Status
Recruiting
Showing {first} - {last} of {total} Results